*仅供医学专业人士阅读参考
“靶化”方案的精准落地取决于NGS检测可及、人群筛选与患者教育
参考文献
[1]DUAN J, et al. Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study[J/OL]. CA: A Cancer Journal for Clinicians, 2026, 76(2): e70071.
[2] ZHOU T, et al. Osimertinib plus chemotherapy versus osimertinib monotherapy in EGFR-mutated advanced non-small cell lung cancer with concurrent TP53 mutations: A randomized, open-label, multicenter, phase 3 study[J/OL]. JAMA, 2026. doi:10.1001/jama.2026.10599.
[3]WANG Z,et al. Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study). 2026ASCO.LBA101.
审核编码：HS-P-A505A-2610-02070 有效期至：2027-10-12
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。
辉煌优配官网提示：文章来自网络，不代表本站观点。
